<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04560894</url>
  </required_header>
  <id_info>
    <org_study_id>SCT-I10A-C301</org_study_id>
    <nct_id>NCT04560894</nct_id>
  </id_info>
  <brief_title>SCT-I10A Plus SCT510 Versus Sorafenib as First-Line Therapy for Advanced Hepatocellular Carcinoma</brief_title>
  <acronym>HCC</acronym>
  <official_title>SCT-I10A in Combination With SCT510 Versus Sorafenib as First-Line Therapy for Advanced Hepatocellular Carcinoma (HCC): A Multicenter, Randomized, Open-label,Phase 2/3 Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sinocelltech Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sinocelltech Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to assess the safety and effectiveness of SCT-I10A in combination&#xD;
      with SCT510 in patients with HCC who have not received prior systemic therapy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 11, 2020</start_date>
  <completion_date type="Anticipated">September 2024</completion_date>
  <primary_completion_date type="Anticipated">April 2024</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>up to 3years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression-free survival(PFS)evaluated by the Blinded Independent Central Review Committee (BICR) based on RECIST V1.1</measure>
    <time_frame>up to 3years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>PFS</measure>
    <time_frame>up to 3years</time_frame>
    <description>PFS evaluated by investigator based on RECIST V1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS</measure>
    <time_frame>up to 3years</time_frame>
    <description>PFS evaluated by BICR based on mRECIST.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>up to 3years</time_frame>
    <description>ORR evaluated by BICR based on RECIST V1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ORR</measure>
    <time_frame>up to 3years</time_frame>
    <description>ORR evaluated by BICR based on mRECIST.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ORR</measure>
    <time_frame>up to 3years</time_frame>
    <description>ORR evaluated by investigator based on RECIST V1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum concentration of SCT-I10A and SCT510</measure>
    <time_frame>up to 3years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-drug antibody (ADA)</measure>
    <time_frame>up to 3years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">621</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>SCT-I10A+SCT510</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Sorafenib</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SCT-I10A</intervention_name>
    <description>Participants receive SCT-I10A intravenously，200mg，d1，Q3w</description>
    <arm_group_label>SCT-I10A+SCT510</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SCT510</intervention_name>
    <description>Participants receive SCT510 intravenously，15mg/kg，d1，Q3w</description>
    <arm_group_label>SCT-I10A+SCT510</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sorafenib 200mg</intervention_name>
    <description>Participants receive sorafenib orally，400mg bid</description>
    <arm_group_label>Sorafenib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participants must have a diagnosis of HCC not suitable for radical surgery and/or&#xD;
             local treatment，or progressed after surgery and/or local treatment.&#xD;
&#xD;
          -  No prior systemic therapy for HCC(End of postoperative adjuvant chemotherapy for more&#xD;
             than 6 months allowed).&#xD;
&#xD;
          -  Child-Pugh ≤7 , no history of hepatic encephalopathy.&#xD;
&#xD;
          -  Barcelona Clinic Liver Cancer stage B, not suitable for local treatment and BCLC C.&#xD;
&#xD;
          -  At least one measurable lesion based on Recist1.1&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.&#xD;
&#xD;
          -  Adequate hematologic and organ function.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Local treatment or surgery for liver lesions within 4 weeks.&#xD;
&#xD;
          -  Prior liver or other organ transplantation.&#xD;
&#xD;
          -  Active Central nervous system (CNS) metastasis or leptomeningeal metastases.&#xD;
&#xD;
          -  Gastrointestinal perforation and/or fistula or intraperitoneal abscess within 6 months&#xD;
             prior to the start of study treatment.&#xD;
&#xD;
          -  Hemorrhage tendency or high-risk for bleeding , severe coagulation disorders.&#xD;
&#xD;
          -  Active known, or suspected autoimmune disease.&#xD;
&#xD;
          -  Any condition that is not suitable for participate in this study as determined by&#xD;
             investigator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>jianming xu, MD</last_name>
    <phone>+8613910866712</phone>
    <email>jmxu2003@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>307 Hospital of PLA</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100071</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>jianming xu, MD</last_name>
      <phone>+8613910866712</phone>
      <email>jmxu2003@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>September 17, 2020</study_first_submitted>
  <study_first_submitted_qc>September 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 23, 2020</study_first_posted>
  <last_update_submitted>November 11, 2020</last_update_submitted>
  <last_update_submitted_qc>November 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sorafenib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

